Samsung Medical Center
Seoul, 06351, South Korea
NCT Number: NCT03381872
The aim of the study is to compare clinical outcomes between intravascular imaging-guided versus angiography-guided percutaneous coronary intervention (PCI) in complex lesions.
This study is active but is not currently recruiting participants.
Notify Me19 year and older
All sexes
Interventional
Not applicable
Seoul, 06351, South Korea
After introduction of the 2nd generation drug-eluting stents (DES), the rates of device-related failure or target lesion failure such as restenosis and stent thrombosis has been markedly decreased, compared with the era of bare metal stents or 1st generation DES. Nevertheless, patients undergoing percutaneous coronary intervention (PCI) for complex lesions, for example, chronic total occlusion (CTO), left main disease, true bifurcation lesion, long lesion, multi-vessel PCI, multiple overlapping stents, or severely calcified lesions have significantly worse clinical outcomes than those with non-complex lesions.
During the PCI procedure, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are useful tools for providing information on preintervention lesion characteristics, including vulnerable plaques, lesion severity, length, and morphology; on postintervention optimal stent implantation for stent expansion, extension, and apposition; and on possible complications after stent implantation. Therefore, intravascular imaging guidance may improve clinical outcomes after complex PCI. However, although previous randomized controlled trial (RCT) and registries showed significantly lower rates of major adverse clinical events following IVUS-guided PCI compared with angiography-guided PCI, the RCTs were limited with small sample size and dealt with very selected lesion subsets such as CTO or long lesion. Moreover, it is uncertain whether OCT-guided PCI improves clinical outcomes compared with angiography-guided PCI. Meanwhile, appropriate imaging modality may differ according to patient and lesion characteristics.
One of the ways to maximize the advantage of intravascular imaging is choice of intravascular imaging devices by the operator's discretion. Therefore, the current RENOVATE-COMPLEX-PCI (Randomized Controlled Trial of Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) is designed to investigate whether PCI under guidance of intravascular imaging devices (IVUS or OCT) chosen by operators would improve clinical outcomes compared with angiography-guided PCI in patients with complex lesions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms
All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
IVUS Reference site: Largest lumen, Plaque burden <50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter
OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: [1] By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm.
[2] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm.
All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
Time frame: 1-year after last patient enrollment
A composite of cardiac death, target vessel MI, and clinically-driven target vessel revascularization
Time frame: 1-year after last patient enrollment
A composite of cardiac death, spontaneous target vessel MI, and clinically-driven target vessel revascularization
Time frame: 1-year after last patient enrollment
Cardiac death or target-vessel related MI
Time frame: 1-year after last patient enrollment
any death
Time frame: 1-year after last patient enrollment
cardiac death
Time frame: 1-year after last patient enrollment
Target vessel MI with procedure-related MI
Time frame: 1-year after last patient enrollment
Target vessel MI without procedure-related MI
Time frame: 1-year after last patient enrollment
Any MI with procedure-related MI
Time frame: 1-year after last patient enrollment
Any MI without procedure-related MI
Time frame: 1-year after last patient enrollment
Non-target vessel related MI
Time frame: 1-year after last patient enrollment
TLR
Time frame: 1-year after last patient enrollment
TVR
Time frame: 1-year after last patient enrollment
clinically-driven revascularization
Time frame: 1-year after last patient enrollment
definite stent thrombosis
Time frame: 48-72 hours after index procedure
CIN was defined as an increase in serum creatinine of ≥0.5mg/dL or ≥25% from baseline within 48-72 hours after contrast agent exposure
Time frame: Immediate after index procedure
Total amount of contrast use during index hospitalization
Time frame: Immediate after index procedure
Total procedure time during index hospitalization
Time frame: 1-year after last patient enrollment
Total medical cost
Time frame: 4 years after last patient enrollment
A composite of cardiac death, target vessel MI, and clinically-driven target vessel revascularization
Time frame: 4 years after last patient enrollment
A composite of cardiac death, spontaneous target vessel MI, and clinically-driven target vessel revascularization
Time frame: 4 years after last patient enrollment
any death
Time frame: 4 years after last patient enrollment
cardiac death
Time frame: 4 years after last patient enrollment
Target vessel MI with procedure-related MI
Time frame: 4 years after last patient enrollment
Target vessel MI without procedure-related MI
Time frame: 4 years after last patient enrollment
Any MI with procedure-related MI
Time frame: 4 years after last patient enrollment
Any MI without procedure-related MI
Time frame: 4 years after last patient enrollment
Non-target vessel related MI
Time frame: 4 years after last patient enrollment
TLR
Time frame: 4 years after last patient enrollment
TVR
Time frame: 4 years after last patient enrollment
clinically-driven revascularization
Time frame: 4 years after last patient enrollment
definite stent thrombosis
Time frame: 4 years after last patient enrollment
BARC Classification (2,3, or 5)
Time frame: 4 years after last patient enrollment
TIMI Classification (Minimal, Minor, Major)
Samsung Medical Center
Other
Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention (RENOVATE-COMPLEX-PCI)
Acronym: RENOVATE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00756379
Arterial Occlusive Diseases, Arteriosclerosis
Houston, Texas, United States
View Trial DetailsNCT01207167
Arterial Occlusive Diseases, Arteriosclerosis
San Francisco, California, United States
View Trial DetailsNCT00005487
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT04073810
Arterial Occlusive Diseases, Arteriosclerosis
Cambridge, United Kingdom
View Trial Details